Michael Landsittel - Mar 28, 2024 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Signature
/s/ Melissa Masse, Attorney-in-Fact
Stock symbol
BPMC
Transactions as of
Mar 28, 2024
Transactions value $
-$294,750
Form type
4
Date filed
4/1/2024, 04:34 PM
Previous filing
Mar 19, 2024
Next filing
May 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $180K +5K +10.57% $36.05 52.3K Mar 28, 2024 Direct F1
transaction BPMC Common Stock Sale -$475K -5K -9.56% $95.00 47.3K Mar 28, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -5K -33.33% $0.00 10K Mar 28, 2024 Common Stock 5K $36.05 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 This option was granted on February 16, 2017 and is fully vested as of the transaction date.